Inclusion Criteria:

- Adult patients with minimal height of 150cm and minimal weight of 50 KG

- Histological confirmed HCC

- with no previous treatment

- With unresectable tumor

- With solitary or multiple intrahepatic tumor, the diameter of the largest one must
larger than 7cm.

- No significant baseline liver dysfunction. Cirrhotic status of Child-Pugh class A
only

- No significant renal impairment (creatinine clearance < 30 mL/minute)

- The following laboratory parameters:

- Platelet count ≥ 60,000/µL

- Hemoglobin ≥ 8.5 g/dL

- Total bilirubin ≤ 1.5 mg/dL

- ASL and AST ≤ 5 x upper limit of normal

- Serum albumin ≥ 35 g/L

- Serum creatinine ≤ 1.5 x upper limit of normal

- INR ≤ 1.5 or a Pt/PTT within normal limits

- Absolute neutrophil count (ANC) > 1,500/mm3

- Ability to understand the protocol and to agree to and sign a written informed
consent document

Exclusion Criteria:

- Avascular tumor

- Main portal vein obstruction without cavernous transformation

- Evidence of hepatic decompensation including esophageal or gastric variceal bleeding
or hepatic encephalopathy

- Obstructive jaundice

- Severe underlying cardiac or renal diseases

- Known or suspected allergy to the investigational agent or any agent given in
association with this trial

- Pregnant or breast-feeding patients.

- History of organ allograft

- Active clinically serious infections

- Any condition that is unstable or which could jeopardize the safety of the patient
and his/her compliance in the study